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Abstract 
 
In mice, the deletion of the STOP protein leads to hyperdopaminergia and major behavioral 
disorders that are alleviated by neuroleptics, hence representing a potential model of 
schizophrenia. The reduction of the glutamatergic synaptic vesicle pool in the hippocampus 
could reflect a disturbance in glutamatergic neurotransmission in this model. Here we 
examined potential disturbances in energy metabolism and interactions between neurons 
and glia in 15 week-old STOP KO, wild type and heterozygous mice. Animals received [1-
13C]glucose and [1,2-13C]acetate, the preferential substrates of neurons and astrocytes, 
respectively. Extracts from the whole forebrain and midbrain were analyzed by HPLC, 13C 
and 1H NMR spectroscopy. Amounts and labeling of most metabolites were unchanged. 
However, glutamine concentration and amount of [4,5-13C]glutamine derived from [1,2-
13C]acetate significantly decreased by 17% and 18%, respectively, in STOP KO compared to 
wild type mice. The amount of [4-13C]glutamate was decreased in STOP KO and 
heterozygous compared to wild type mice. GABA labeling was not influenced by the 
genotype. Since STOP deficient mice have a lower synaptic vesicle density, less glutamate 
is released to the synaptic cleft leading to decreased stimulation of the postsynaptic 
glutamate receptors, reflecting increased glutamine metabolism only in the vicinity of the 
postsynapse of STOP KO mice.  
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Introduction 
 
In the past twenty years, a neurodevelopmental origin for schizophrenia has become the 
prevailing pathogenic hypothesis for the disorder (Harrison, 1999; Marenco and Weinberger, 
2000). Schizophrenia is regarded as a disease mainly expressed at the synapse level on the 
basis of both the hypothesis of a functional disconnection (Friston, 2002) and the data from 
genetic studies using DNA microarrays (Mirnics et al., 2001). For a long time, the 
“dopaminergic hypothesis” of schizophrenia based on the hyperactivity of the dopaminergic 
system was the prevailing hypothesis for the disease. Indeed, it is well known that 
amphetamine and cocaine that release or inhibit the reuptake of dopamine, respectively, 
induce psychosis (Seeman, 1987). However, a dysfunctioning of other neurotransmission 
systems has also been postulated and a more recent view includes disturbances also at the 
level of serotonin and glutamate neurotransmissions (Carlsson et al., 2001).  
The “glutamatergic hypothesis” of schizophrenia comes from the observation that N-
methyl-D-aspartate (NMDA) glutamate-receptor antagonists, such as phencyclidine 
(Halberstadt, 1995) and ketamine (Lahti et al., 1995) have been shown to cause strong 
psychotomimetic effects with hallucinations and psychomotor signs. In contrast to 
dopaminergic agonists, which only mimic the positive symptoms of schizophrenia, NMDA 
antagonists produce the whole spectrum including negative and cognitive symptoms. The 
proposed mechanisms for a dysfunction of glutamatergic neurotransmission include 
interactions between the dopaminergic and glutamatergic systems (Carlsson et al., 2001), 
excitotoxic neuronal damage in hippocampus and cortex (Deutsch et al., 2001) and 
alterations in glutamine and glutamate metabolism (Brenner et al., 2005; Eyolfsson et al., 
2006; Kondziella et al., 2005). It has been suggested that the dysregulation of dopamine 
transmission in schizophrenia may be secondary to alterations in glutamatergic NMDA 
receptor-mediated transmission (Carlsson et al., 2004; Olney and Farber, 1995). Indeed, in 
healthy volunteers receiving ketamine, the amplitude of amphetamine-induced dopamine 
release was significantly enhanced compared to control conditions (Kegeles et al., 2000). 
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Thus, the elevated dopamine release seen in schizophrenic patients after amphetamine 
administration may well be secondary to a failure in glutamatergic control of dopamine 
neurons. This hypothesis is supported by experimental studies in rats (Miller and 
Abercrombie, 1996).  
Glutamate is the most important excitatory neurotransmitter in the mammalian brain. In 
the basal state, 60-75% of the total cortical glucose utilization corresponds to glutamatergic 
neuron activity, 10-15% reflect GABAergic neurotransmission and 10-15% glial needs 
(Lebon et al., 2002; Shulman et al., 2004; Sibson et al., 2001). The synthesis of glutamate 
and GABA in neurons is closely connected to astrocytic metabolism and the homeostasis of 
glutamate is crucial to brain function for many reasons. Firstly, fast removal of glutamate 
from the synaptic cleft by astrocytes is necessary for short glutamate action on the 
postsynaptic target cell and thereby precise information signaling. Secondly, high 
extracellular concentration of glutamate is neurotoxic and excessive glutamate release may 
participate in the pathophysiology of many brain disorders, possibly involving schizophrenia 
(Deutsch et al., 2001). Thirdly, since neurons lack the main anaplerotic enzyme in the brain, 
pyruvate carboxylase (Shank et al., 1985), they depend on astrocytic supply of tricarboxylic 
acid (TCA) cycle intermediates because the constant loss of amino acid neurotransmitters 
from neurons would otherwise lead to restriction of neurotransmitter precursors (Sonnewald 
et al., 1993). After being released from neurons, glutamate is cleared from the synapses by 
astrocytes, which transform glutamate to glutamine via glutamine synthetase which is an 
astrocyte specific enzyme (Norenberg and Martinez-Hernandez, 1979). Astrocytes release 
glutamine into the extracellular space, from where it is taken up by neurons and converted 
back to glutamate and GABA or enters the TCA cycle via 2-oxoglutarate to provide carbon 
skeletons for the synthesis of other metabolites. This shuttling between astrocytes and 
neurons is called the “glutamine-glutamate cycle” (Berl and Clark, 1983).  
An excellent tool to study metabolic pathways and glial-neuronal metabolic interactions 
is 13C nuclear magnetic resonance spectroscopy (NMRS) (see Sonnewald and Kondziella, 
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2003 for review). The simultaneous injection of [1,2-13C] acetate and [1-13C]glucose allows to 
study astrocytic and neuronal metabolism in the same animal (Taylor et al., 1996). In the 
present work, this technique was applied to the characterization of neuronal and astrocytic 
metabolism in STOP (Stable Tubule only Polypeptide) protein knockout (KO) mice which 
have been proposed to be a “meaningful model for the study of the pathophysiology of 
schizophrenia” (Brun et al., 2005). The STOP protein is a protein involved in the cold stability 
of microtubules, synaptic plasticity and neurotransmission (Andrieux et al., 2002). The 
deletion of the STOP protein leads to a decrease in synaptic vesicle density in hippocampal 
CA1 terminals, impaired long term potentiation and depression at the level of Schaffer 
collaterals-CA1 pyramidal cell synapses. STOP KO mice are also characterized by 
disorganized activity with frequent shifts between hyperlocomotion and prostration, anxiety-
related behavior, inability to perform object recognition tasks and social withdrawal (Andrieux 
et al., 2002). These mice also exhibit increased dopaminergic neurotransmission and 
increased efflux of dopamine in the nucleus accumbens upon stimulation (Brun et al., 2005). 
Taken together, these studies indicate the association between limbic hyper-dopaminergy 
and hippocampal hypo-glutamatergy in these mice (Andrieux et al., 2002; Brun et al., 2005). 
To study the cerebral metabolism of glutamate further, we explored the metabolic fate of [1-
13C]glucose and [1,2-13C]acetate using 13C and 1H NMRS, and HPLC in the brain of wild type 
(WT), heterozygous and STOP KO mice. Acetate and glucose are both precursors for acetyl-
CoA which enters the TCA cycle. Whereas acetyl-CoA from glucose is metabolized more in 
the neuronal TCA cycle (Qu et al., 2000), acetate is metabolized predominantly in astrocytes 
since it is selectively taken up into these cells (Waniewski and Martin, 1998).  
 
Materials and Methods  
 
STOP KO male mice (STOP-/-), heterozygous (STOP+/-) and control WT littermates 
(STOP+/+), 15 week-old, were generated as previously described (Andrieux et al., 2002). 
Mice were housed eight per cage and maintained in quiet, uncrowded facilities (room 
temperature of 22ºC ± 1°C) on a 12 hour light-dark schedule (7:00 a.m., lights on), humidity 
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60%, and given unlimited access to lab chow and water. Males only were used for these 
experiments to eliminate confounding effects of variable estrogen level on neuronal 
excitability (Murphy et al., 1998). All animal experimentation was performed in accordance 
with the rules of the European Committee Council Direction of November 24, 1986 
(86/69/EEC) and the French Department of Agriculture (Licence N°67-97). The animals (10 
in each group) were injected intraperitoneally with [1-13C]glucose (543mg/kg, 0.3 M solution) 
and [1,2-13C]acetate (504mg/kg, 0.6 M solution) followed by decapitation twenty minutes 
later. The heads were immediately frozen in liquid nitrogen and stored at -80ºC. Brains were 
removed from the slightly thawed skull, and because of their small size and limitations of 
sensitivity of the method, the forebrain/midbrain (cerebrum) including cerebral cortex and 
subcortical regions was used. The brainstem and cerebellum were discarded. The tissue was 
homogenized in 7% (w/v) perchloric acid and centrifuged at 4,000 g for 5 min. The procedure 
was repeated, the supernatants pooled and neutralized with 1 M KOH followed by 
lyophilization. 
 
High Pressure Liquid Chromatography (HPLC) 
Amino acids in cell extracts and medium were quantified by HPLC on a Hewlett Packard 
1100 system (Agilent Technologies, Palo Alto, CA, USA). The amino acids were pre-column 
derivatized with o-phthaldialdehyde (Geddes and Wood, 1984) and subsequently separated 
on a ZORBAX SB-C18 (4.6 × 250 mm, 5 µm) column from Agilent using a phosphate buffer 
(50 mM, pH = 5.9) and a solution of methanol (98.75 %) and tetrahydrofurane (1.25 %) as 
eluents. The separated amino acids were detected with fluorescence and quantified by 
comparison to a standard curve derived from standard solutions of amino acids run after 
every twelve samples.   
 
13C NMR spectroscopy 
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Proton decoupled 125.77 MHz 13C NMR spectra were obtained using a Bruker DRX-500 
spectrometer after the samples had been re-dissolved in 300 μL D2O containing ethylene 
glycol 0.1% as an internal standard. Scans were accumulated with a 30º pulse angle and 25 
kHz spectral width with 64K data points. The number of scans was 9000. The acquisition 
time was 1.308 s, the relaxation delay 0.5 s.  
 
1H NMR spectroscopy 
 
A DRX-500 spectrometer was used to obtain 1H NMR spectra with a sweep width of 8 kHz 
with 32K data points. The pulse angle was 90°, the acquisition time 2.045 s and the 
relaxation delay was 10 s. The number of scans was 250. Water suppression was set at the 
residual H2O resonance. 
 
Labeling patterns 
 
Most of the singlet peaks in the NMR spectrum (Figure 1) represent label from [1-
13C]glucose. In contrast, the doublets seen in the spectrum are mostly derived from [1,2-
13C]acetate and thus astrocytic metabolism (Waniewski and Martin, 1998). [1-13C]glucose is 
converted to pyruvate via glycolysis and can form [3-13C]alanine and [3-13C]lactate. Pyruvate 
may enter the TCA cycle via [2-13C ]acetyl-CoA, which will lead to the formation of [4-
13C]glutamate and glutamine or [2-13C]GABA. If the 13C label stays for a second turn in the 
TCA cycle the [2-13C] or [3-13C] positions of glutamate and glutamine or the [3-13C] or [4-13C] 
positions of GABA can be labeled. Alternatively, in astrocytes, pyruvate can be carboxylated 
by pyruvate carboxylase (PC) to oxalacetate, which can lead to the synthesis of [2-
13C]glutamate and glutamine or [4-13C]GABA. [1,2-13C]Acetate can also be converted to 
acetyl-CoA, however, the product, [1,2-13C]acetyl-CoA, will have two 13C atoms resulting in 
doublet formation. Thus, [4,5-13C]glutamate and glutamine or [1,2-13C]GABA are formed 
(Figure 2). After the second turn of the TCA cycle this label will be in the [1,2-13C] or [3-13C] 
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positions of glutamate and glutamine and the [2-13C] or [3-13C] positions of GABA. Glutamine 
is labeled more from [1,2-13C]acetate (doublet) than from [1-13C]glucose (singlet); the 
opposite is the case for glutamate and GABA. Alanine, lactate, N-acetylaspartate (NAA) in 
the C-6 position and succinate are mainly labeled from glucose. Creatine, taurine and the 
aspartate group in N-acetylaspartate are not labeled during the 20 min period of the present 
experiment; the naturally abundant 13C gives rise to the observed singlets in Figure 1. Since 
both acetyl-CoA and oxalacetate can be labeled or unlabeled, the number of possible 
isotopomers of the TCA cycle derived metabolites is large and only compounds derived from 
the first and the second turns are presented in Figure 2. Metabolic ratios were calculated but 
no differences were detected between groups (for details see Melø et al., 2006; Brenner et 
al., 2005). 
 
Data analysis 
 
The amounts of 13C in the different metabolites were quantified from integrals of the relevant 
peaks obtained from NMR spectra with ethylene glycol as an internal standard. Factors for 
nuclear Overhauser and relaxation effects were applied to all spectra. Amounts of 
metabolites were quantified either from 1H NMR spectra using ethylene glycol as internal 
standard and correcting for number of protons or by HPLC. 
All results are given as means ± standard deviation. Statistics were performed using the 
two-tailed, unpaired Student’s t-test; p <0.05 was considered significant. 
Results  
 
In the three genotypes, brain levels of all amino acids related to the TCA cycle and taurine, 
glutathione, succinate, lactate and NAD+ were similar. The only difference was a significant 
(17%) decrease in the cerebral concentration of glutamine of STOP KO compared to WT 
mice (Table 1). 
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 Injection of [1-13C]glucose and [1,2-13C]acetate lead to efficient labeling of many 
metabolites (Figure 1). Particularly, labeling of glutamate and glutamine C-3 and C-4, GABA 
C-2 and C-3, aspartate and lactate C-3 are shown in Figure 1. Labeling patterns from [1-
13C]glucose and [1,2-13C]acetate from the first and second turns of the TCA cycle are shown 
in Figure 2. The amount of [4,5-13C]glutamine, derived from [1,2-13C]acetate, was significantly 
decreased by 18% in STOP KO compared to WT mice (Figure 3). The amount of [4,5-
13C]glutamate tended to be decreased in STOP+/- and STOP-/- mice compared to control 
animals but the difference was not significant. Levels of [1,2-13C]GABA were similar in the 
three genotypes. Label from [1-13C]glucose in the form of [4-13C]glutamate and [4-
13C]aspartate was decreased by 16% and 21% respectively in KO STOP compared to wild 
type mice while the labeling of [2-13C]GABA and [4-13C]GABA did not depend on the 
genotype. The pyruvate carboxylase/dehydrogenase (PC/PDH) ratios were calculated and 
no significant differences between the groups were detected (data not shown). Generally, 
carboxylation was low in all groups. 
 
Discussion 
 
The cytosolic step of neuronal glutamate and astrocytic glutamine metabolism were affected 
in the STOP KO mouse, whereas mitochondrial metabolism appeared unchanged. We 
propose that glutamine metabolism is decreased in major parts of the astrocytes of STOP 
KO mice, but unaltered in areas close to the presynapse and decreased in the vicinity of the 
postsynapse.  
 The STOP protein is a protein involved in the cold stability of microtubules, synaptic 
plasticity and neurotransmission (Andrieux et al., 2002). Different isoforms of the STOP 
protein are expressed in neurons and astrocytes (Galiano et al., 2004) and it has been 
shown that in knockout mouse embryos, microtubule cold stability was lost in both neurons 
and glial cells while being partly preserved in heterozygous mice (Andrieux et al., 2002). This 
mouse model was used in the present study and a decreased level of glutamine was found in 
- 9 - 
the cerebrum of homozygous KO compared to WT mice. The glutamine level in 
heterozygous mice was not significantly different from both wild type and knockout mice, 
indicating that reduced amounts of the STOP protein are sufficient for maintaining glutamine 
synthesis. As in STOP deficient mice, reduced amounts of glutamine were found in the left 
anterior cingulate cortex of patients with chronic schizophrenia in addition to reduction in 
glutamate (Theberge et al., 2003). This decrease of glutamate and glutamine could possibly 
be an effect of long term treatment with neuroleptics, but the authors argue that this is 
unlikely and the present study supports this view. Two 1H NMR spectroscopy studies of 
patients with never treated first episode schizophrenia, showed increased levels of glutamine 
in the medial prefrontal cortex and the left anterior cingulate cortex and thalamus, 
respectively (Bartha et al., 1997; Theberge et al., 2002). Taken together, these reports 
indicate that first episode schizophrenic patients have an increased glutamine level in 
specific areas of the brain, whereas chronic patients have decreased levels of glutamate and 
glutamine. Thus, it appears that the 15-week-old STOP KO mice mimic chronic 
schizophrenia but not first episode schizophrenia, and hence STOP KO mice might be a 
good model for chronic schizophrenia.  
In the present study, a significant decrease was found in the amount of [4,5 
13C]glutamine which is derived from [1,2-13C]acetate and therefore from astrocytic 
metabolism, indicating decreased glutamine synthesis in the STOP KO mice. A similar 
decrease was observed in the rat model of schizophrenia induced by the chronic injection of 
MK801 (Kondziella et al., 2005). Pyruvate carboxylation, another astrocyte specific pathway, 
was not changed compared to WT or heterozygous mice. It is conceivable that changes in 
microtubule stability will affect cytosolic enzymes such as glutamine synthetase (GS), 
whereas pyruvate carboxylase (PC), located on/in mitochondria was not affected. Other 
cytosolic enzymes, those related to glycolysis appeared unaffected, since the amounts of 
lactate and alanine were unchanged. The osmolyte taurine, the antioxidant glutathione and 
energy metabolism related NAD+ were unchanged as well. As stated in the introduction, the 
astrocytes supply neurons with glutamine which can be converted to glutamate by the 
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mitochondrial enzyme phosphate activated glutaminase (PAG). It is also important to note in 
this context that most of the glutamate in brain is located in glutamatergic neurons (Ottersen 
and Storm Mathisen 1986). Since the amount of [4,5-13C]glutamine was decreased in the 
present study in STOP KO compared to WT mice, a decreased level of [4,5-13C]glutamate 
would be expected, since the latter is directly derived from [4,5-13C]glutamine via PAG. 
However, no decrease was observed. The amount of [4,5-13C]glutamate in STOP KO 
animals was at the control level. This could be due to decreased catabolism of [4,5-
13C]glutamate, increased PAG activity or normal release of [4,5-13C]glutamine, despite lower 
intracellular amounts. The fact that also [1,2-13C]GABA, another neuronal metabolite derived 
from [4,5-13C]glutamine, was unchanged, indicates that the latter situation is most likely 
occurring. 
The labeling (data not shown) and concentrations of the metabolites associated with 
primarily neuronal mitochondria, such as N-acetylaspartate, succinate and aspartate 
(Baslow, 2003; Palaiologos et al., 1988; Sonnewald et al., 1996) were similar in STOP KO, 
heterozygous and WT mice. A decrease was found in glutamate labeled from [1-13C]glucose, 
i.e. [4-13C]glutamate which is derived from neuronal metabolism, in the STOP KO mice 
compared to WT. A decrease in [4-13C]glutamate concentration was also observed in the 
chronic MK801 rat model of schizophrenia (Kondziella et al., 2005). Levels of [2-13C]GABA 
were unchanged in the STOP KO mice but decreased in MK801-treated rats. The decrease 
in [4-13C]glutamate in the STOP KO mice could indicate that the cytosolic glutamate 
synthesis from 2-oxoglutarate was impaired as a result of microtubule instability. Glutamate 
in neurons (mostly [4-13C]glutamate) is accumulated into vesicles and released. As 
mentioned above, this glutamate can be converted to [4-13C]glutamine in the astrocytes for 
future transport to neurons. However, in spite of a reduction in the amount of [4-
13C]glutamate, no change was detected in [4-13C]glutamine concentration. This could 
possibly reflect increased GS activity, which is inconsistent with the decrease in GS activity 
that we postulated above in the light of decreased labeling of [4,5-13C]glutamine. However, 
the cerebral metabolism of glutamate in astrocytes is compartmentalized and there have to 
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be domains, which release glutamine, that is taken up by the neuronal cell body (Figure 4). 
We postulate that GS activity is decreased in regions of the astrocyte that are close to the 
non-synaptic parts of neurons (Figure 4 [1]), leading to decreased amounts of [4-
13C]glutamine. However, in the synaptic region other mechanisms apply (Figure 4 [3,4,5]). 
Glutamate is released from vesicles docking the presynaptic membrane. Previous reports 
have shown that STOP KO mice have a lower synaptic vesicle density (Andrieux et al., 
2002). This indicates that less glutamate is released to the synaptic cleft leading to 
decreased stimulation of the postsynaptic glutamate receptors. Upon depolarization, the 
activation of NMDA receptors by glutamate allows Ca2+ influx through the ion channel. Ca2+ 
entry into the postsynaptic neuron activates nitric oxide synthase (NOS) through a second 
messenger pathway involving calmodulin (Kosenko et al., 2003). Nitric oxide (NO) 
synthesized in the postsynaptic neuron does not only affect the post- and presynaptic neuron 
but also the nearby astrocyte resulting in tonic inhibition of GS (Kosenko et al., 2003). 
Reduced presynaptic glutamate release would then, through disinhibition of the astrocytic 
GS, cause increased glutamine production in the astrocyte (Figure 4 [3,4,5]). Indeed the 
unchanged amount of [4-13C]glutamine in the presence of decreased [4-13C]glutamate could 
support this hypothesis. Modification of GS activity due to changes in NMDA receptor 
stimulation has been reported previously by Brenner et al. (2005). In that study, rats received 
a single injection of the NMDA receptor antagonist MK-801, a model for schizophrenia; 
increased GS activity was postulated in astrocyte processes close to the postsynaptic neuron 
(Brenner et al., 2005). 
 
In conclusion, the results of the present study support previous indications that STOP KO 
mice have reduced synaptic glutamate release and are in a hypoglutamatergic state. 
Hypoglutamatergia is thought to be an important causal mechanism of schizophrenia. STOP 
KO mice also show signs of hyperdopaminergia (Brun et al., 2005). This, together with the 
reduction in glutamine levels, makes the STOP KO mouse a valid model of chronic 
schizophrenia and supports the hypothesis that dysregulation of dopamine in schizophrenia 
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coexists with and may be secondary to alterations in glutamatergic NMDA receptor-mediated 
transmission (Carlsson et al., 2004; Olney and Farber, 1995). 
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Legends of figures 
 
Figure 1: 13C NMR spectrum of cerebrum extract from STOP KO mice injected with [1,2-
13C]acetate and [1-13C]glucose. Peak assignments; 1: glutamate C-2; 2: glutamine C-2; 3: 
aspartate C-2; 4: aspartate C-3; 5: GABA C-2; 6: succinate C-2/C-3; 7: glutamate C-4; 8: 
glutamine C-4; 9: glutamate C-3; 10: glutamine C-3; 11: GABA C-3; 12: N-acetylaspartate C-
3; 13: lactate C-3; 14: alanine C-3. The singlets are mostly derived from [1-13C]glucose and 
the doublets in the spectrum from [1,2-13C]acetate. 
 
Figure 2: Schematic representation of 13C labeling of glutamate, glutamine, GABA and 
aspartate originating from [1-13C]glucose (a) or [1,2-13C]acetate (b). Filled circles represent 
13C and empty circles 12C. TCA, tricarboxylic acid cycle; Glu, glutamate; Gln, glutamine. 
 
Figure 3: Amount of 13C labeled metabolites (nmol/g tissue) derived from [1-13C]glucose 
(figure a) and [1,2-13C]acetate (figure b). Data represent means ± S.D. of 10 mice in each 
group. * p<0.05, statistically significant difference from wild type mice.  
 
Figure 4: Schematic representation of the glutamate-glutamine cycle related interactions of 
an astrocyte with a pre- and postsynaptic neuron. (1) [1,2-13C]Acetate is taken up by 
astrocytes, but not by neurons. Through the tricarboxylic cycle (TCA), [1,2-13C]acetatyl CoA 
is converted to [4,5-13C]glutamate. Glutamine synthetase (GS) converts [4,5-13C]glutamate to 
[4,5-13C]glutamine. We postulate that the STOP KO mice have a decreased GS activity in 
this non-synaptic region of the astrocyte. (2) Glucose is mostly taken up by neurons. 
[1-13C]glucose is after several steps converted to [4-13C]glutamate. In the STOP KO mice 
neuronal cytosolic glutamate synthesis is decreased. (3) Microtubule instability in the STOP 
KO mice probably leads to reduced synaptic glutamate release. (4) NMDA receptors are 
activated by synaptic glutamate and allow influx of Ca2+ into the postsynaptic dendrite. Ca2+ 
activates the enzyme nitric oxide synthase (NOS). (5) NO may diffuse into the astrocyte 
- 16 - 
where it normally inhibits GS. In the STOP KO mice, reduced activation of NMDA receptors 
by glutamate leads to reduced NO production resulting in less inhibition of GS. This will only 
be the case in the part of the astrocyte close to the synapse. Abbreviations: 4,5-Gln, 
[4,5-13C]glutamine; 4,5-Glu, [4,5-13C]glutamate; 4-Gln, [4-13C]glutamine; 4-Glu, 
[4-13C]glutamate; GS, glutamine synthetase; NO, nitric oxide; NOS, nitric oxide synthase; 
Pyr, pyruvate; TCA, tricarboxylic acid cycle. 
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